Virios therapeutics granted new patent for antiviral inhibitor combination

Atlanta--(business wire)---- $viri #antiviral--virios therapeutics, inc. (nasdaq: viri), a clinical-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, announced today that the united states patent and trademark office (“uspto”) has granted virios therapeutics patent exclusivity on its valacyclovir-celecoxib combination drug candidate to 2033. the company's intellectual property portfolio now includes 21 issued patents, consisting of 13 iss
VIRI Ratings Summary
VIRI Quant Ranking